Schering-Plough fertility drug succeeds in Phase III
This article was originally published in Scrip
Schering-Plough's investigational single-injection fertility treatment corifollitropin alfa has met its primary endpoints in a Phase III non-inferiority trial comparing the drug with seven daily injections of recombinant follicle-stimulating hormone (FSH).
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.